AVANIR Pharmaceuticals to Present at UBS Warburg Global Life Sciences Conference

NEW YORK--(BUSINESS WIRE)--Sept. 24, 2003--AVANIR Pharmaceuticals (AMEX: AVN) announced that it is participating in the UBS Warburg Global Life Sciences Conference taking place September 22 - 25, 2003, at The Plaza Hotel in New York. In his presentation, scheduled for 12:00 p.m., September 24, 2003, President and Chief Executive Officer Dr. Gerald J. Yakatan will focus on AVANIR's drug candidates in clinical development.

AVANIR's lead product, Neurodex(TM), is a late stage, first-in-class drug candidate for central nervous system disorders that targets two distinct patient populations. Neurodex is in Phase III clinical development for the treatment of pseudobulbar affect in neurodegenerative diseases, including Alzheimer's, multiple sclerosis, Lou Gehrig's disease or ALS, Parkinson's, traumatic brain injury and stroke. AVANIR is currently enrolling multiple sclerosis patients in a final Phase III study and anticipates submitting an NDA in 2004. In June 2003, AVANIR completed a successful Phase II clinical trial studying Neurodex in patients with diabetic neuropathic pain.

AVANIR's allergy and asthma drug candidate, AVP 13358, is in a Phase I clinical trial. AVP 13358 is an orally active compound designed to counteract the body's response to allergens by selectively inhibiting the production of the critical mediator (IgE) and a group of Th2 cytokines (Il-4, Il-5, Il-13) that play key roles in the pathogenesis of allergy and asthma.

AVANIR Pharmaceuticals is a drug discovery and development company focused on the development of treatments for central nervous system disorders and inflammatory diseases. The company's first commercialized FDA-approved product, Abreva(R), is marketed in North America by GlaxoSmithKline and is the leading over-the-counter product for the treatment of cold sores. The company's lead product candidate, Neurodex(TM), is in Phase III clinical development for pseudobulbar affect and in Phase II clinical development for neuropathic pain. An internally developed small molecule, AVP 13358, is in a Phase I clinical trial for the treatment of allergy and asthma. Using its proprietary Xenerex(TM) technology, AVANIR also develops human monoclonal antibodies for infectious diseases and other therapeutic applications. Further information about AVANIR can be found at www.avanir.com.

The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect". The company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

CONTACT: Redington Inc.
Thomas Redington, 203-222-7399
tredington@redingtoninc.com
or
AVANIR Pharmaceuticals
Patrice Saxon, 858-622-5202
psaxon@avanir.com

SOURCE: AVANIR Pharmaceuticals